Comparable stake leader
AI Biotechnology LLC
SEC ownership of Zura Bio Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001855644.
Disclosed value leader
AI Biotechnology LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ZURA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
AI Biotechnology LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
AI Biotechnology LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001855644
- Issuer location
- La Jolla, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Zura Bio Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AI Biotechnology LLC
Disclosed value leader
AI Biotechnology LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
13D/G row: AI Biotechnology LLC
Showing 1-8 of 50 holder rows.
Quick read
AI Biotechnology LLC leads the comparable SEC ownership view at 18%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AI Biotechnology LLC's linked filing trail.
Comparable ownership
Top 5
AI Biotechnology LLC
18%
Athanor Capital
16%
Venrock Healthcare Capital Partne...
9.9%
MONTANOVA CAPITAL, LLC
9.9%
RA CAPITAL MANAGEMENT, L.P.
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AI Biotechnology LLC |
13D/G
3/4/5
10%+ Owner
|
18%
|
$103,223,132
19,699,071 shares
|
+$28,154,420 | 26 Feb 2026 |
| Athanor Capital |
13D/G
3/4/5
10%+ Owner
|
16%
|
$60,678,440
11,581,402 shares
|
$0 | 23 Jan 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.9%
|
$59,192,796
9,816,384 shares
|
+$20,882,077 | 31 Mar 2026 |
| MONTANOVA CAPITAL, LLC |
13D/G
13F
Suvretta Capital Management, LLC · Company
|
9.9%
|
$57,431,306
9,524,263 shares
|
+$23,862,290 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
4.9%
|
$4,633,204
3,217,503 shares
|
$0 | 31 Dec 2024 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
4.7%
|
$26,962,035
4,471,316 shares
|
-$1,212,633 | 30 Apr 2026 |
| PFIZER INC |
13D/G
3/4/5
13F
Pfizer Inc. 13-5315170 · 10%+ Owner · Company
|
4.6%
|
$4,276,832
2,970,022 shares
|
$0 | 31 Dec 2024 |
| GREAT POINT PARTNERS LLC |
13D/G
13F
Company
|
4.4%
|
$25,422,058
4,215,930 shares
|
+$2,412,000 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$12,500,000.
Buys
$12,500,000
Insiders: 1
Sells
$0
Insiders: 0
Net
+$12,500,000
Shares: +2,000,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 2,000,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 2,000,000 | 0 | $12,500,000 | $0 | +$12,500,000 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 35 reporting-owner rows connected to Zura Bio Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
35
Largest Forms 3/4/5 holder
Athanor Capital
Net 12M change
+$12,500,000
Latest report
17 Jun 2026
Recent insider transactions for Zura Bio Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer Jarrett | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Parvinder Thiara | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Steven J. Schoch | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Ajay Nirula | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Amit Munshi | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Mark Eisner | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Daniel J. Becker | ZURA | Share Option (Right to Buy) | Award | 51,000 | 51,000 | 17 Jun 2026 | Direct | |||
| Gary Whale | ZURA | Employee Share Option (Right to Buy) | Award | 263,000 | 263,000 | 01 Apr 2026 | Direct | |||
| Kiran Nistala | ZURA | Employee Share Option (Right to Buy) | Award | 340,900 | 340,900 | 01 Apr 2026 | Direct | |||
| Eric J. Hyllengren | ZURA | Employee Share Option (Right to Buy) | Award | 340,900 | 340,900 | 01 Apr 2026 | Direct | |||
| Kim Davis | ZURA | Employee Share Option (Right to Buy) | Award | 425,700 | 425,700 | 01 Apr 2026 | Direct | |||
| Sandeep Chidambar Kulkarni | ZURA | Employee Share Option (Right to Buy) | Award | 894,000 | 894,000 | 01 Apr 2026 | Direct | |||
| AI Biotechnology LLC | ZURA | Class A Ordinary Shares | Purchase | 43.9% | $12,500,000 | $6.25 | 2,000,000 | 6,552,725 | 26 Feb 2026 | Direct |
| Ajay Nirula | ZURA | Share Option (Right to Buy) | Award | 37,812 | 37,812 | 21 Feb 2026 | Direct | |||
| Mark Eisner | ZURA | Share Option (Right to Buy) | Award | 37,812 | 37,812 | 21 Feb 2026 | Direct | |||
| Parvinder Thiara | ZURA | Share Option (Right to Buy) | Award | 38,823 | 38,823 | 23 Jan 2026 | Direct | |||
| Sandeep Chidambar Kulkarni | ZURA | Employee Share Option (Right to Buy) | Award | 2,934,107 | 2,934,107 | 21 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.